- Home
- BMN vs CGEN Comparison
BMN vs CGEN Comparison
Compare BMN & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMN | CGEN |
|---|---|---|
| Founded | 2020 | 1993 |
| Country | United States | Israel |
| Employees | 19800 | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.6M | 143.1M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | BMN | CGEN |
|---|---|---|
| Price | $26.02 | $1.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 29.9K | ★ 458.5K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 4.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $231.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.51 | $1.13 |
| 52 Week High | $25.59 | $2.66 |
Technical Indicators
Market Signals| Indicator | BMN | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 55.37 |
| Support Level | $25.97 | $1.43 |
| Resistance Level | $26.09 | $1.73 |
| Average True Range (ATR) | 0.32 | 0.07 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 75.53 | 67.83 |
Price Performance
Historical ComparisonAbout BMN BlackRock 2037 Municipal Target Term Trust of Beneficial Interest
BlackRock 2037 Mun Tgt is a non-diversified, closed-end management investment company. The Trust's investment objective is to provide current income that is exempt from regular federal income tax. The Trust invests in investment grade quality securities or securities that are unrated but judged to be of comparable quality by the investment adviser.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.